Euclidean Capital LLC 13F: Quarter-over-Quarter Portfolio Changes
Euclidean Capital LLC reported a disclosed portfolio value of approximately $392.3 million in its latest SEC Form 13F-HR filing for Q1 2026, up 6.2% quarter on quarter. Over the quarter, the family office bought more shares in 1 holding and exited 2 positions.
Euclidean Capital LLC's top buy was Vanguard Intl Equity Index F (VEU) . The family office bought 8.5% more shares, lifting the position's portfolio weight by 2.6 percentage points. Its top sell was State Str Spdr S&p 500 ETF T (SPY) . The family office exited the position completely after it had accounted for 0.8% of the previous portfolio.
Top BuysQ1 2026
The family office's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| VANGUARD INTL EQUITY INDEX F | VEU | +2.6% | +8.5% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| STATE STR SPDR S&P 500 ETF T | SPY | 0.8% |
| RAPT THERAPEUTICS INC | RAPT | 0.8% |
Net Portfolio Value ChangeQ1 2026
- $0.4BPrior quarter
- $0.4BCurrent quarter
- +$0.0BNet delta
- +6.2%% change
Methodology & FAQ
How Euclidean Capital LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Euclidean Capital LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Euclidean Capital LLC buy in Q1 2026?
In Q1 2026, Euclidean Capital LLC bought more shares of VANGUARD INTL EQUITY INDEX F (VEU).
What stocks did Euclidean Capital LLC sell in Q1 2026?
In Q1 2026, Euclidean Capital LLC fully sold 2 positions (STATE STR SPDR S&P 500 ETF T (SPY), RAPT THERAPEUTICS INC (RAPT)).
Which positions did Euclidean Capital LLC initiate in Q1 2026?
Euclidean Capital LLC established no new positions in Q1 2026.
Which existing positions saw the largest allocation increases for Euclidean Capital LLC in Q1 2026?
Of 1 existing position with share-count increases in Q1 2026, the largest were: VANGUARD INTL EQUITY INDEX F (VEU, +2.6% weight, +8.5% shares).
Which positions did Euclidean Capital LLC fully exit in Q1 2026?
Euclidean Capital LLC fully exited 2 positions in Q1 2026: STATE STR SPDR S&P 500 ETF T (SPY, last-reported weight 0.8%), RAPT THERAPEUTICS INC (RAPT, last-reported weight 0.8%).
Which existing positions saw the largest allocation reductions for Euclidean Capital LLC in Q1 2026?
Euclidean Capital LLC reported no material allocation reductions in existing positions in Q1 2026.
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.